Roger Paredes, MD, PhD, is Head of the Infectious Diseases Department, Hospital Germans Trias i Pujol and Principal Investigator of the Microbial Genomics Group at the IrsiCaixa AIDS Research Institute, Badalona, Catalonia, Spain. He obtained an MD, PhD degree in Medicine and Surgery from the Autonomous University of Barcelona (UAB) and specialised in HIV research at the Brigham & Women’s Hospital, Harvard Medical School, through a La Caixa grant for postgraduate studies. His team at irsiCaixa has demonstrated the clinical utility of HIV-1 deep sequencing in both high- and low-income countries, and is now leading pioneering research into the role of the gut microbiome in the pathogenesis of HIV infection and chronic inflammation. During the COVID-19 pandemic, Dr Paredes has been the Spanish National Coordinator of seminal NIH/NIAID-funded randomized clinical trials, including ACTT-1 and 2 and the ACTIV-3/TICO platform, which have defined the current standard of care for this disease in hospitalized patients as well as in outpatients. Dr. Paredes is member of the COVID-19 treatment guidelines of the Spanish ID Society and the Catalan Institute of Health. He is also member of the WHO Global Clinical Platform for COVID-19 Clinical Advisory Group and serves in the WHO’s HIV Drug Resistance Strategy Steering Committee, the HIV treatment guidelines group and the European Laboratory Initiative.
